POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINES
- 1 January 1978
- journal article
- research article
- Vol. 56 (3) , 371-375
Abstract
A 14-valent pneumococcal vaccine was recently licensed for general use after extensive testing in humans. Antibody production was satisfactory in 92% of individuals and a highly significant (76-92%) reduction was found in the rates for pneumococcal pneumonias caused by the capsular types present in the vaccine. Children over 2 yr of age respond well to the vaccine, but younger children may not respond satisfactorily to some capsular types. In adults, the duration of the protective effect is unknown, but no substantial booster response was seen after a 2nd dose at 1 yr. Such a booster dose induced a marked increase in the degree of local reaction at the injection site.This publication has 5 references indexed in Scilit:
- 7. Prevention of Pneumococcal Pneumonia by VaccinationPublished by University of Pennsylvania Press ,1985
- Vaccination and Revaccination with Polyvalent Pneumococcal Polysaccharide Vaccines in Adults and InfantsExperimental Biology and Medicine, 1978
- Protective efficacy of pneumococcal polysaccharide vaccinesJAMA, 1977
- Studies in Human Subjects of Polyvalent Pneumococcal VaccinesExperimental Biology and Medicine, 1977